{"ok":true,"entity":{"id":"repligen","name":"Repligen","entityType":"company","officialName":"Repligen Corporation","canonicalName":"Repligen","displayName":"Repligen","category":"バイオプロセス技術企業（バイオ医薬品製造向け）","shortDescription":"Repligen Corporation（Nasdaq: RGEN）は米マサチューセッツ州ウォルサムに本社を置き、バイオ医薬品の製造に使うバイオプロセス技術（接線流ろ過、クロマトグラフィー、プロセス分析、シングルユース流体管理）を提供する企業。2026年10月6日にBioLife Solutionsの買収を完了したと同社が発表し、2026年6月30日終了四半期の総売上高は2億412万8,000米ドルだった。","primaryCluster":"life-science-tools","parentEntity":null,"verificationStatus":"draft","website":"https://www.repligen.com/","updatedAt":"2026-10-29T04:31:31.488Z","secondaryClusters":[],"alias":["Repligen Corporation","レプリジェン"],"searchKeywords":["レプリジェン","Repligen","RGEN","バイオプロセス","接線流ろ過","TFF","クロマトグラフィー","プロセス分析","シングルユース","BioLife Solutions 買収"]},"referenceIndex":["P-01-001","P-02-001","P-04-001","P-05-001","P-06-001"]}